Abstract Expression of the receptor tyrosine kinase HER3 is negatively correlated with survival in ovarian cancer, and HER3 overexpression is associated with cancer progression and therapeutic resistance. Thus, improvements in HER3-targeted therapy could lead to significant clinical impact for ovarian cancer patients. Previous work from our group established multivalency as a potential strategy to improve the therapeutic efficacy of HER3-targeted ligands, including affibodies....
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract The incidences of thyroid cancer keep rising worldwide over the past few decades. Although most thyroid cancers are indolent and ...
-
Abstract Amyloid beta peptide (Aβ), the main component of senile plaques of Alzheimer’s disease brains, is produced by sequential cleavage ...
-
Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis Juvenile myelomonocytic leukemia: a s...
-
ACS Nano DOI: 10.1021/acsnano.7b02426 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h1neaG via...
-
Abstract Background Hyponatremia is associated with the increased risk of early and late mortality in patients with cardiac disease. Thi...
-
We set out to estimate net survival trends for 10 common cancers in 279 cancer registry populations in 67 countries around the world, as par...
-
Abstract Objectives Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet...
-
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2B38rkA via IFTTT
-
Publication date: Available online 17 January 2018 Source: Journal of Infection and Chemotherapy Author(s): Nobuyasu Hirai, Kei Kasahara, ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου